COPENHAGEN – With the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress holding an in-person conference for the first time in two years, Korean professors also had the chance to show off their recent research in the field.Notably, Professor Jung Jae-hyun of the Department of R
COPENHAGEN – Bristol Myers Squibb’s deucravacitinib, a lupus treatment candidate, drew keen attention from global rheumatologists as the company unveiled the phase 2 study at the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress Saturday.The phase 2 PAISLEY study evaluated deu
COPENHAGEN -- Celltrion aims to gain the upper hand in the fiercely competitive infliximab biosimilar market through direct selling Remsima SC, a top manager said Thursday."Currently, competition for infliximab biosimilars is cut-throat," Celltrion Vice President Choi Byoung-seo said during an inter
COPENHAGEN -- A new analysis of the phase 3 clinical trial showed that Remsima SC (Ingredient: infliximab) made a significantly greater improvement in clinical outcomes compared to the intravenous (IV) in patients with rheumatoid arthritis (RA).The post-hoc study focused on confirming whether the nu
COPENHAGEN – The 2022 European Alliance of Associations for Rheumatology (EULAR 2022) European Congress of Rheumatology kicked off its 75th Scientific Assembly and Annual Meeting in Copenhagen, Denmark, on Wednesday.After two years of an online-only event due to the Covid-19 pandemic, EULAR has deci
COPENHAGEN -- The 2022 European Alliance of Associations for Rheumatology (EULAR 2022) European Congress of Rheumatology kicked off its four day-run on Wednesday.Many multinational pharmaceutical companies, including Celltrion of Korea, joined the convention, setting up booths to introduce the lates